News Appeal finds NICE must reconsider Alzheimer's drugs Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.
News First MHRA/NICE aligned guidance due in June The aligned regulatory pathway for UK drugs regulator MHRA and reimbursement authority NICE gets underway on 1st April.
News NHS cleared to use Astellas' non-hormonal menopause drug Around half a million women will soon be able to access Astellas' Veoza treatment for symptoms like hot flushes associated with menopause.
News NICE says no to Genmab cervical cancer therapy Genmab's recently approved therapy for relapsed cervical cancer has been turned down for NHS use in initial NICE guidance.
News Joy as NICE changes tack on first NHS vitiligo treatment NHS patients in England with vitiligo will soon be able to access Incyte's Opzelura, the first drug shown to reverse the skin-lightening disorder.
News NICE backs changes to NHS' diabetes care pathway New guidance from NICE on type 2 diabetes management will shake up NHS treatment, with wider use of both SGLT2 inhibitors and GLP-1 agonists.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.